| 0 (0%) | 09-27 09:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 82.51 | 1-year : | 96.37 |
| Resists | First : | 70.64 | Second : | 82.51 |
| Pivot price | 68.34 |
|||
| Supports | First : | 65.79 | Second : | 62.79 |
| MAs | MA(5) : | 68.52 |
MA(20) : | 67.88 |
| MA(100) : | 58.85 |
MA(250) : | 50.73 |
|
| MACD | MACD : | 0.8  |
Signal : | 0.9 |
| %K %D | K(14,3) : | 61 |
D(3) : | 65.6 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 70.64 | Low : | 33.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRUS ] has closed below upper band by 33.6%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 69.57 - 69.91 | 69.91 - 70.2 |
| Low: | 67.61 - 68 | 68 - 68.34 |
| Close: | 68.31 - 68.91 | 68.91 - 69.43 |
Sun, 21 Sep 2025
Does Analyst Enthusiasm for Immuno-Oncology Strengthen the Long-Term Case for Merus (MRUS)? - simplywall.st
Wed, 17 Sep 2025
Merus (MRUS) Coverage Initiated by Barclays with Overweight Rati - GuruFocus
Thu, 28 Aug 2025
Oncology Innovator Merus to Showcase Multispecific Antibody Pipeline at Wells Fargo Healthcare Event - Stock Titan
Wed, 13 Aug 2025
Overcoming the pain: BYU’s Mrus battled past serious injury to reach his dream - heraldextra.com
Tue, 05 Aug 2025
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Fri, 11 Jul 2025
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 6.561e+007 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 4,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.4453e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 250 % |
| Return on Equity (ttm) | -23.2 % |
| Qtrly Rev. Growth | 5.623e+007 % |
| Gross Profit (p.s.) | 17.14 |
| Sales Per Share | -40.79 |
| EBITDA (p.s.) | -4.43866e+007 |
| Qtrly Earnings Growth | -5.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -313 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.69 |
| Price to Cash Flow | 7.35 |
| Dividend | 0 |
| Forward Dividend | 4.36e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|